Kang Qin

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Advanced Non Small Cell Lung Cancer

Health Insurance

Epidermal Growth Factor Receptor

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Kang Qin, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M Hubert, Xiuning Li, Natalie Vokes, Kunal Rai, Ara Vaporciyan, Don L Gibbons, John V Heymach, Jiun-Kae Jack Lee, Scott E Woodman, Caroline Chung, David A Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16 (5) (2024)
Kang Qin, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M Hubert, Xiuning Li, Natalie Vokes, Kunal Rai, Ara Vaporciyan, Don L Gibbons, John V Heymach, Jiun-Kae Jack Lee, Scott E Woodman, Caroline Chung, David A Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16 (5) (2024)
Kang Qin, Kaiwen Wang, Shenduo Li, Lingzhi Hong, Priyadharshini Padmakumar, Rinsurongkawong Waree, Shawna M Hubert, Xiuning Li, Natalie Vokes, Kunal Rai, Ara Vaporciyan, Don L Gibbons, John V Heymach, Jiun-Kae Jack Lee, Scott E Woodman, Caroline Chung, David A Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang
Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16 (5) (2024)
Kang Qin, Lingzhi Hong, Jianjun Zhang, Xiuning Le
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities. Cancers 15 (3) (2023)
Kang Qin, Lingzhi Hong, Jianjun Zhang, Xiuning Le
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities. Cancers 15 (3) (2023)